Photodynamic therapy for enhancing antitumour immunity

Biomedical Papers

Volumn 156, Issue 2, 2012, Pages 93-102

  Pizova, Klara ^a   Tomankova, Katerina ^a   Daskova, Adela ^a   Binder, Svatopluk ^a   Bajgar, Robert ^a   Kolarova, Hana ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Antibody; Antitumour imunity; Cancer; Photodynamic therapy; Photosensititizer

Indexed keywords

CYTOKINE; PHOTOSENSITIZING AGENT;

ADAPTIVE IMMUNITY; ANIMAL; COMPLEMENT ACTIVATION; DRUG EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; METHODOLOGY; NEOPLASM; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; REVIEW; SECRETION (PROCESS);

ADAPTIVE IMMUNITY; ANIMALS; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; NEOPLASMS; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84863992196     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.056     Document Type: Review

References (80)

1. Kolarova H, Tomankova K, Bajgar R, Kolar P, Kubinek R. Photodynamic and sonodynamic treatment by phthalocyanine on cancer cell lines. Ultrasound Med Biol 2009;35:1397-404.
2. Rob ertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B 2009;96:1-8.
3. Olivo M, Bhuvaneswari R, Lucky SS, Dendukuri N and Soo-Ping Thong P. Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor Modalities. Pharmaceuticals 2010;3:1507-29.
4. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011;61:250-81.
5. Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008;10:148-54.
6. O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009;85:1053-74.
7. Nowis D, Stokłosa T, Legat M, Issat T, Jakóbisiak M, Goła{ogonek}b J. The influence of photodynamic therapy on the immune response. Photodiagnosis and Photodynamic Therapy 2005;2:283-98.
8. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010;46:216-226.
9. Jemec GBE. Photodynamic therapy. In: Jemec GBE, Kemeny L, Miech D, editors. Non-Surgical Treatment of Keratinocyte Skin Cancer. Heidelberg, Dordrecht, London, New York: Springer; 2010. p.133-5.
10. Ryter SW, Gomer CJ. Nuclear factor kappa B binding activity in mouse L1210 cells following photofrin II-mediated photosensitization. Photochem Photobiol 1993;58:753-6.
11. Legrand-Poels S, Bours V, Piret B, Pflaum M, Epe B, Rentier B, Piette J. Transcription factor NF-kappa B is activated by photosensitization generating oxidative DNA damages. J Biol Chem 1995;270:6925-34.
12. Matroule JY, Bonizzi G, Morlière P, Paillous N, Santus R, Bours V, Piette J. Pyropheophorbide-a methyl ester-mediated photosensitization activates transcription factor NF-kappaB through the interleukin-1 receptor-dependent signaling pathway. J Biol Chem 1999;274:2988-3000.
13. Granville DJ, Carthy CM, Jiang H, Levy JG, McManus BM, Matroule JY, Piette J, Hunt DW. Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood 2000;95:256-62.
14. Kick G, Messer G, Goetz A, Plewig G, Kind P. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding. Cancer Res 1995;55:2373-9.
15. Gollnick SO, Lee BY, Vaughan L, Owczarczak B, Henderson BW. Activation of the IL-10 gene promoter following photodynamic therapy of murine keratinocytes. Photochem Photobiol 2001a;73:170-7.
16. Wild PJ, Krieg RC, Seidl J, Stoehr R, Reher K, Hofmann C, Louhelainen J, Rosenthal A, Hartmann A, Pilarsky C, Bosserhoff AK, Knuechel R. RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Mol Cancer Ther 2005;4:516-28.
17. Ruhdorfer S, Sanovic R, Sander V, Krammer B, Verwanger T. Gene expression profiling of the human carcinoma cell line A-431 after 5-aminolevulinic acid-based photodynamic treatment. Int J Oncol 2007;30:1253-62.
18. Sanovic R, Krammer B, Grumboeck S, Verwanger T. Time-resolved gene expression profiling of human squamous cell carcinoma cells during the apoptosis process induced by photodynamic treatment with hypericin. Int J Oncol 2009;35:921-39.
19. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, Wang WC, Unger E, Henderson BW. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;88:1772-9.
20. Seshadri M, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem Photobiol 2009;85:50-6.
21. Yom SS, Busch TM, Friedberg JS, Wileyto EP, Smith D, Glatstein E, Hahn SM. Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol 2003;78:75-81.
22. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 2005;65:1018-26.
23. Kushibiki T, Tajiri T, Tomioka Y, Awazu K. Photodynamic therapy induces interleukin secretion from dendritic cells. Int J Clin Exp Med 2010;3:110-4.
24. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and antitumour immunity. Nat Rev Cancer 2006;6:535-45.
25. Garg AD, Nowis D, Goła{ogonek}b J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010;15:1050-71.
26. Firczuk M, No wis D, Goła{ogonek}b J. PDT-induced inflammatory and host responses. Photochem Photobiol Sci 2011;10:653-63.
27. Cecic I, Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 2002;183:43-51.
28. Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol 2001;74:712-20.
29. Cecic I, Sun J, Korbelik M. Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells. Photochem Photobiol 2006a;82:558-62.
30. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010;20:34-50.
31. Tegla CA, Cudrici C, Patel S, Trippe R 3rd, Rus V, Niculescu F, Rus H. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 2011;51:45-60.
32. Korbelik M, Sun J, Cecic I, Serrano K. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors. Photochem Photobiol Sci 2004;3:812-6.
33. Cecic I, Serrano K, Gyongyossy-Issa M, Korbelik M. Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy. Cancer Lett 2005;225:215-23.
34. Korbelik M. Complement upregulation in photodynamic therapytreated tumors: Role of Toll-like receptor pathway and NFkappaB. Cancer Lett 2009;281:232-8.
35. van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003; 207:105-13.
36. Cecic I, Stott B, Korbelik M. Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int Immunopharmacol 2006b;6:1259-66.
37. Cecic I, Minchinton AI, Korbelik M. The impact of complement activation on tumor oxygenation during photodynamic therapy. Photochem Photobiol 2007;83:1049-55.
38. Cecic I, Korbelik M. Deposition of complement proteins on cells treated by photodynamic therapy in vitro. J Environ Pathol Toxicol Oncol 2006;25:189-203.
39. Stott B, Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol Immunother 2007;56:649-58.
40. Korbelik M, Cec IC I Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J Photochem Photobiol B 2008;93:53-9.
41. Morgan BP, Marc hbank KJ, Longhi MP, Harris CL, Gallimore AM. Complement: central to innate immunity and bridging to adaptive responses, Immunol Lett 2005;97:171-9.
42. Kemper C, Atkin son JP. T-cell regulation: with complements from innate immunity, Nat Rev Immunol 2007;7:9-18.
43. Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A, Salomon Y. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 2009;58:71-84.
44. Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer 2007;96:1839-48.
45. Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 2007;8:950-2.
46. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 2009;15:4460-6.
47. Elmets CA, Bowe n KD. Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. Cancer Res 1986;46:1608-11.
48. Musser DA, Oseroff AR. Characteristics of the immunosuppression induced by cutaneous photodynamic therapy: persistence, antigen specificity and cell type involved. Photochem Photobiol 2001;73:518-24.
49. Gollnick SO, Musser DA, Oseroff AR, Vaughan L, Owczarczak B, Henderson BW. IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response. Photochem Photobiol 2001b;74:811-6.
50. Hayami J, Okamoto H, Sugihara A, Horio T. Immunosuppressive effects of photodynamic therapy by topical aminolevulinic acid. J Dermatol 2007;34:320-7.
51. Yusuf N, Katiyar SK, Elmets CA. The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4+ and CD8+ T cells and can be adoptively transferred to naive recipients. Photochem Photobiol 2008;84(2):366-70.
52. Matthews YJ, Damian DL. Topical photodynamic therapy is immunosuppressive in humans. Br J Dermatol 2010;162:637-41.
53. Hunt DW, Levy JG. Immunomodulatory aspects of photodynamic therapy. Expert Opin Investig Drugs 1998;7:57-64.
54. Qiang YG, Yow CM, Huang Z. Combination of photodynamic therapy and immunomodulation: current status and future trends. Med Res Rev 2008;28:632-44.
55. Kwitniewski M, Juzeniene A, Glosnicka R, Moan J. Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy? Photochem Photobiol Sci 2008;7:1011-7.
56. Goła{ogonek}b J, Wilczyński G, Zagożdżon R, Stokłosa T, Dabrowska A, Rybczyńska J, Wa{ogonek}sik M, Machaj E, Ołdak T, Kozar K, Kamiński R, Giermasz A, Czajka A, Lasek W, Feleszko W, Jakóbisiak M. Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer 2000;82:1485-91.
57. Bellnier DA. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. J Photochem Photobiol B 1991;8:203-10.
58. Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 2003;63:7584-90.
59. Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT, Bellnier DA. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res 2005;11:4241-50.
60. Korbelik M, Cooper PD. Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin. Br J Cancer 2007;96:67-72.
61. Akramiene D, Aleksandraviciene C, Grazeliene G, Zalinkevicius R, Suziedelis K, Didziapetriene J, Simonsen U, Stankevicius E, Kevelaitis E. Potentiating effect of beta-glucans on photodynamic therapy of implanted cancer cells in mice. Tohoku J Exp Med 2010;220:299-306.
62. Separovic D, Bielawski J, Pierce JS, Merchant S, Tarca AL, Bhatti G, Ogretmen B, Korbelik M. Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response. Int J Oncol 2011;38:521-7.
63. Coupienne I, Bontems S, Dewaele M, Rubio N, Habraken Y, Fulda S, Agostinis P, Piette J. NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochem Pharmacol 2011;81:606-16.
64. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibodyhematoporphyrin conjugates. J Immunol 1983;130:1473-7.
65. Hasan T. Phot osensitizer delivery mediated by macromolecular carrier systems. In: Henderson BW, Dougherty TJ, editor. Photodynamic therapy: basic principles and clinical applications. New York: Marcel Dekker, Inc; 1992. p.187-200.
66. Sternberg ED, Dolphin D, Brückner C. Porphyrinbased photosensitizers for use in photodynamic therapy. Tetrahedron 1998;54:4151-202.
67. Yarmush ML, Thorpe WP, Strong L, Rakestraw SL, Toner M, Tompkins RG. Antibody Targeted Photolysis. Crit Rev Ther Drug Carrier Syst 1993;10:197-252.
68. Savellano MD, Hasan T. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem Photobiol 2003;77:431-9.
69. Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 2005;65:6371-9.
70. Bhatti M, Yahioglu G, Milgrom LR, Garcia-Maya M, Chester KA, Deonarain MP. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int J Cancer 2008;122:1155-63.
71. Jalili A, Makowski M, Switaj T, Nowis D, Wilczynski GM, Wilczek E, Chorazy-Massalska M, Radzikowska A, Maslinski W, Biały L, Sienko J, Sieron A, Adamek M, Basak G, Mróz P, Krasnodebski IW, Jakóbisiak M, Gołab J. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 2004;10:4498-508.
72. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 2006;12:2568-74.
73. del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, Pogue B, Hasan T. Synergism of epidermal growth factor receptortargeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. Natl Cancer Inst 2005;97:1516-24.
74. Jiang F, Zhang X, Kalkanis SN, Zhang Z, Yang H, Katakowski M, Hong X, Zheng X, Zhu Z, Chopp M. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma. Photochem Photobiol 2008;84:128-37.
75. Bhuvaneswari R, Thong PS, Gan YY, Soo KC, Olivo M. Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy. J Biomed Opt 2010;15:011114.
76. Korbelik, M., Sun, J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006;55:900-9.
77. Korbelik M. Photodynamic therapy-generated cancer vaccines. Methods Mol Biol 2010;635:147-53.
78. Korbelik M, Stott B, Sun J. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression. Br J Cancer 2007;97:1381-7.
79. Zhang H, Ma W, Li Y. Generation of effective vaccines against liver cancer by using photodynamic therapy. Lasers Med Sci 2009;24:549-52.
80. Shixiang Y, Xi S, Junliang L, Shanyi Z, Xingke X, Meiguang Z, Kai W, Fangcheng L. Antitumor efficacy of a photodynamic therapy-generated dendritic cell glioma vaccine. Med Oncol 2010 [Epub ahead of print] doi:10.1007/s12032-010-9713-y